This technology is a composition for preventing and treating muscle diseases that uses the sesquiterpene derivative alpha-cedrene or its pharmaceutically acceptable salts as an active ingredient. It is widely applicable in pharmaceuticals, health functional foods, and cosmetic compositions for muscle regeneration, increasing muscle mass, and improving muscle function.
As aging leads to an increase in sarcopenia, the risks of gait impairment, insulin resistance, and cardiovascular disease are rising, yet there have been no approved drugs for treating sarcopenia. While myostatin inhibitors and drug repurposing approaches are under development, there has been a lack of practical, commercialized alternatives.
This technology enables alpha-cedrene to increase the expression of p-4E-BP1 and p-p70S6K in the muscle protein synthesis pathway while reducing the expression of MuRF1, MaFbx, and Myostatin—which are involved in muscle protein degradation—at the mRNA level. This simultaneously induces muscle differentiation, regeneration, and strength enhancement. It can be applied to sarcopenia treatments and health supplements for senior muscle strength, providing a new material for the market of geriatric muscle diseases that currently lacks effective treatments.
EP3643302B1, US2021-0369640A1, WO2018-236186A1